검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Inavolisib |
Overview Company | GBG Forschungs GmbH |
Overview Modality | ADC |
Overview Target | Metastatic Breast Cancer |
Overview Indication | HER2-positive Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 15 h |
PK/PD Species | Dog, Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, Monkey, Dog, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Dog, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, Monkey, Dog, In vitro |
Toxicology Major finding | Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer.. The clinical benefit of available treatments in metastatic hormone receptor (HR)+/HER2-breast cancer (BC) remains limited due to the onset of resistance mechanisms, hence the need for increasingly personalized therapies targeting specific molecular alterations. In … |
Clinical Primary efficacy | ORR 11.5% |
Clinical ORR | 11.5% |
Clinical PFS | 4.24 |
Clinical Result source | ClinicalTrials.gov NCT04632992 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Inavolisib |
Overview Company | GBG Forschungs GmbH |
Overview Modality | ADC |
Overview Target | Metastatic Breast Cancer |
Overview Indication | HER2-positive Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 15 h |
PK/PD Species | Dog, Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, Monkey, Dog, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Dog, Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, Monkey, Dog, In vitro |
Toxicology Major finding | Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer.. The clinical benefit of available treatments in metastatic hormone receptor (HR)+/HER2-breast cancer (BC) remains limited due to the onset of resistance mechanisms, hence the need for increasingly personalized therapies targeting specific molecular alterations. In … |
Clinical Primary efficacy | ORR 11.5% |
Clinical ORR | 11.5% |
Clinical PFS | 4.24 |
Clinical Result source | ClinicalTrials.gov NCT04632992 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교